Men with a high risk of prostate cancer recurrence could live longer if hormone treatment is given alongside radiotherapy after surgery, a new study has suggested.

Prostate cancer that has become resistant to hormone treatment and that does not respond to radiation or chemotherapy requires new methods of treatment.

Conclusion: LAMS have inhibitory effects on RM-1 in tumor-bearing mice, but do not affect the immune function. Furthermore, LAMS has no side effects on chemotherapy drugs such as CY.